NeuroTherapeutics Pharma is a Chicago-based biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company develops compounds that act through a specific mechanism of action; its lead molecule is NTP-2014. These compounds have potential application across multiple diseases, including epilepsy, pain and other CNS indications. NeuroTherapeutics closed a $43M Series B financing to fund its programs. The new capital will enable advancement of NTP-2014 up to and through multiple proof-of-concept Phase II trials and support further development of a pipeline to expand this new class of therapy. As part of the financing, two investors’ representatives—Luke Evnin of MPM Capital and Elaine Jones of Pfizer Venture Investments—will join the company’s board of directors. NeuroTherapeutics Pharma, based in Chicago, IL, focuses on developing novel therapies for central nervous system disorders. Its lead program is NTP-2014, which the company plans to advance through multiple proof-of-concept Phase II trials. The company intends to further develop a pipeline to expand this new class of therapy. NeuroTherapeutics is backed by Novo Ventures and Thomas, McNerney and Partners and is currently raising a Series B financing to support development. Recently it received a $100,000 investment from the Epilepsy Therapy Project. The Series B is intended to advance NTP-2014 through Phase II trials and fund broader pipeline development.

Total raised

$43M

Funding rounds

2

Latest round

Series B

Latest activity

May 2010